Why the study?
Does prophylactic ganciclovir early after heart transplantation prevent the development of transplant coronary artery disease?
Population
149 consecutive patients after heart transplantation on immunosuppression consisting of muromonab-CD3…
Comparison
Ganciclovir administered during the initial 28… vs Placebo administered during the initial 28 days…
Design
RCT, randomized
Follow-up
mean 4.7+/-1.3 years
Authors
Loading...
Supports ganciclovir prophylaxis to lower TxCAD risk after heart transplant; extends RCT evidence for antiviral strategies in this setting.
Does prophylactic ganciclovir early after heart transplantation prevent the development of transplant coronary artery disease?
Prophylactic ganciclovir early after heart transplantation may reduce the incidence of transplant coronary artery disease, particularly in patients not receiving calcium channel blockers.
Valantine et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: